



## Advances in the Pathobiology, Diagnosis and Treatment of Chronic Myeloid Neoplasms

Guest Editors:

**Dr. Luis Colomo**

Department of Pathology,  
Hematopathology Section,  
Hospital del Mar, Institute of  
Investigacions Mediques-IMIM,  
Universitat Pompeu Fabra  
Barcelona, 08003 Barcelona,  
Spain

**Dr. Xavier Calvo**

1. Hematological Cytology  
Laboratory, Pathology  
Department, Hospital del Mar,  
08003 Barcelona, Spain  
2. Translational Research on  
Hematological Neoplasms  
Group, Cancer Research  
Program, Hospital del Mar  
Research Institute (HMRI), 08003  
Barcelona, Spain

Deadline for manuscript  
submissions:  
**closed (31 July 2021)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue focuses on myelodysplastic syndromes (MDS), chronic myeloproliferative neoplasms (MPN), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). The Revised 4th Edition of the WHO Classification of Haematopoietic and Lymphoid Tissues has introduced many changes in the terminology and diagnostic approach of MDS and MDS/MPN, as well as recent knowledge regarding molecular and genetic alterations of MPN. Many questions remain unresolved and active research is ongoing in this field, and new clinicopathological entities and molecular-genetic findings have been recently described.

The purpose of this Special Issue is to offer recent studies focusing on the biology, diagnostic features, and treatment of chronic myeloid neoplasms. Original research articles and reviews are both welcome.

Dr. Luis Colomo  
Dr. Xavier Calvo  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)